durvalumab,tremelimumab
astrazeneca
[]
infinity trial presentation at asco #gi23: neoadjuvant durvalumab and tremelimumab immunotherapy in early-stage mmrd gastric/goj adenocarcinoma: 60% pathological complete response rate. small numbers, but further evidence that immunotherapy highly effective. 
Academic GI Cancer Centre in the City of London. Delivering evidence-based treatments and clinical trials to patients. Informing and education patients and HCPs